Sep 13, 2021 / 01:30PM GMT
Thibault Boutherin - Morgan Stanley, Research Division - Equity Analyst
Good morning, and good afternoon, everyone. Thank you for joining this session at the Morgan Stanley Global Healthcare Conference. My name is Thibault Boutherin. I'm part of pharmaceuticals equity research team based in London. Before we start, I need to refer to important disclosures. (technical difficulty) as Morgan Stanley research. Would you like to start with some introductory comments on the current situation and the outlook for Indivior?
Mark Crossley - Indivior PLC - CEO & Executive Director
Thanks, Thibault and thanks for having us here today. And how poignant that this is national recovery month here in the U.S. for us to get together and talk about Indivior. I think Indivior is at a great spot with regards to its development and its future, just the strategic sort of options we have in front of us.
We've come out of material overhangs on the business in a very good spot. And for us, the way forward is extremely clear. We basically have a 4-pronged strategy as we move
Indivior PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers